Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Clene Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CLNN
Nasdaq
8731
https://clene.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Clene Inc.
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
- Mar 19th, 2024 12:30 pm
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
- Mar 15th, 2024 12:00 pm
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
- Mar 13th, 2024 12:00 pm
Clene to Present at the 36th Annual ROTH Conference
- Mar 7th, 2024 1:00 pm
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
- Feb 29th, 2024 1:00 pm
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
- Feb 22nd, 2024 1:00 pm
Clene Inc. announces positive results from CNM-Au8 results from MS trial
- Feb 5th, 2024 7:30 pm
Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment
- Jan 24th, 2024 1:30 pm
Clene Announces Significant Positive Results from LTE VISIONARY-MS Trial
- Jan 10th, 2024 2:00 pm
Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension
- Jan 8th, 2024 12:00 pm
Clene's Phase 2 REPAIR-PD and REPAIR-MD Trials Support Advancement to Phase 3
- Jan 3rd, 2024 9:25 pm
Clene Announces New Data from HEALEY ALS Platform Trial
- Dec 22nd, 2023 8:00 pm
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
- Dec 21st, 2023 12:00 pm
Clene Provides Update on ALS Clinical Development Meeting With FDA
- Dec 21st, 2023 12:00 pm
How Clene CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders
- Dec 19th, 2023 2:00 pm
Clene Lead Drug Candidate Featured in Peer-Reviewed Publication
- Dec 15th, 2023 8:00 pm
Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases
- Dec 14th, 2023 1:36 pm
Clene's Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients
- Dec 12th, 2023 1:30 pm
Nobel Prize in Chemistry's Spotlight on Nanotechnology Shines Light on Clene Efforts to Develop Catalytically Active Nanoparticles
- Dec 8th, 2023 7:19 pm
Clene Capitalizing on Promising Chemical and Therapeutic Properties of Nanocrystals
- Nov 23rd, 2023 2:00 pm
Scroll